BACKGROUND: In this study, we compared liver function tests after hepatectomy with inflow occlusion as a function of propofol versus sevoflurane anesthesia. METHODS: One hundred patients undergoing elective liver resection with inflow occlusion were randomized into a sevoflurane group or a propofol group. General anesthesia was induced with 3 g/kg fentanyl, 0.2 mg/kg cisatracurium, and target-controlled infusion of propofol, set at a plasma target concentration of 4 to 6 g/mL, or sevoflurane initially started at 8%. Anesthesia was maintained with target-controlled infusion of propofol (2-4 g/mL) or sevoflurane (1.5%-2.5%). The primary end point was postoperative liver injury assessed by peak values of liver transaminases. RESULTS: Transaminase levels peaked between the first and the third postoperative day. Peak alanine aminotransferase was 504 and 571 U/L in the sevoflurane group and the propofol group, respectively. Peak aspartate aminotransferase was 435 U/L after sevoflurane and 581 U/L in the propofol group. There were no significant differences in peak alanine aminotransferase or peak aspartate aminotransferase between groups. Other liver function tests including bilirubin and alkaline phosphatase, and peak values of white blood cell counts and creatinine, were also not different between groups. CONCLUSIONS: Sevoflurane and propofol anesthetics resulted in similar patterns of liver function tests after hepatectomy with inflow occlusion. These data suggest that the 2 anesthetics are equivalent in this clinical context.
I nflow occlusion by clamping of the portal triad (Pringle maneuver) is routinely used in many centers [1] [2] [3] to prevent blood loss during liver transsection. 4, 5 However, the Pringle maneuver induces ischemic injury in the remnant liver, which is associated with increased morbidity and mortality. 6 Diseased livers such as steatotic or fibrotic livers may be the most vulnerable to temporary interruption of blood flow. [7] [8] [9] Although volatile anesthetics and propofol have been studied and compared in ischemia/reperfusion injuries in many organ systems, few studies have compared volatile anesthetics and propofol for liver resection with inflow occlusion. In this study, we compared sevoflurane-and propofol-based anesthetics for hepatectomy with inflow occlusion, using indices of postoperative liver function as the major end point for comparison.
METHODS
One hundred consecutive ASA physical status I/II/III patients undergoing elective liver resection with inflow occlusion between July 2009 and December 2009 were assessed for study eligibility. Exclusion criteria were age Ͻ18 years, additional ablation therapies (cryosurgery or radiofrequency ablation), prior liver resection for donation, or scheduled resection not requiring inflow occlusion. Enrolled patients were randomized at the beginning of the operation into a sevoflurane group (inhaled anesthesia with sevoflurane) or a propofol group (target-controlled infusion of propofol). All other anesthetic and surgical management was the same. The randomization sequence without any stratification was generated by computer and sealed with consecutively numbered envelopes providing concealment of random allocation. The study was approved by our local institutional research ethics committee. Written informed patient consent was obtained from all participants.
All patients received oral midazolam (5.0 mg) and IM atropine (0.5 mg) as a premedication. Electrocardiogram, radial arterial blood pressure, arterial oxygen saturation, and bispectral index were monitored routinely. Epidural catheters were placed at T7-10 interspaces before anesthesia, and a test dose of lidocaine was injected. A bolus of 7 to 10 mL ropivacaine 0.75% was administered epidurally after induction of anesthesia. In the propofol group, general anesthesia was induced with 3 g/kg fentanyl, followed by a target-controlled infusion of propofol, set at a plasma target concentration of 4 to 6 g/mL, and 0.2 mg/kg cisatracurium. In the sevoflurane group, anesthesia was induced with 3 g/kg fentanyl, sevoflurane initially started at 8%, and 0.2 mg/kg cisatracurium. After tracheal intubation, anesthesia was maintained with a target-controlled infusion of propofol (in the propofol group, as above) or sevoflurane (1.5%-2.5%), fentanyl 1 to 2 g/kg, and cisatracurium 5-to 10-mg boluses according to clinical needs. To keep arterial mean blood pressure at a target of 60 mm Hg, we administered 2 to 5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 dopamine as indicated. Depth of anesthesia was determined with the bispectral index with a target range between 35 and 45 during surgery. Epidural catheters were removed after the operation. Intravenous analgesia (continuous IV infusion of 1000 mg tramadol and 100 g sufentanil over 48 hours) was continued in all patients postoperatively.
Surgical procedures were performed in a standardized manner under the supervision of 2 experienced hepatobiliary surgeons. After mobilization of the liver, inflow occlusion was achieved by the tourniquet technique around the portal triad with a 4-mm Mersilene tape. During resections, a low central venous pressure (0 -5 mm Hg) was maintained. The length of time for continuous inflow occlusion was determined by the surgeons. All patients received the same chemotherapy regimen before and after surgery.
Each patient was followed for the entire hospitalization. The primary end point was postoperative hepatocyte injury defined by peak alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels over 6 postoperative days. Additional end points were peak values of white blood cells, bilirubin, alkaline phosphatase, creatinine levels, and length of hospital stay. All outcome variables were measured before and 1, 3, and 6 days after surgery. Additionally, cirrhosis (yes/no) was defined by histologic evaluation.
Group sample size was calculated based on differences in postoperative peak ALT concentration in a pilot study of patients who received propofol anesthesia (685 Ϯ 392 U/L) and sevoflurane anesthesia (487 Ϯ 308 U/L). The following formula: n ϭ 15.7/ES 2 ϩ 1, where ES ϭ effect size ϭ (difference between groups)/(mean of the SD between groups), with ␣ ϭ 0.05 and power ϭ 0.8 was used to determine that the study would be adequately powered with n ϭ 50 per group. 10 We compared peak transaminases (primary outcome) between groups using a linear regression model with peak transaminases as the dependent and group allocation as the independent variable (corresponding to a 2-sample t test). In addition, we adjusted these comparisons for baseline transaminases and bilirubin levels, ischemic (Pringle) time, size of excised liver (cm 3 ), and blood loss in multivariable linear regression analyses (analysis of covariance). The other measurement data were also compared using a 2-sample t test, and count data were compared using 2 . Hepatic function in patients with cirrhosis might be more sensitive to inflow occlusion than without cirrhosis. Therefore, we conducted a limited number of subgroup analyses to assess the effect of cirrhosis (yes/no) on postoperative hepatocyte injury (ALT/AST) using a 2-sample t test. All analyses were conducted using SPSS 16.0 (SPSS Inc., Chicago, IL). Results were expressed as the mean Ϯ SD. A P value Ͻ0.05 was considered to represent statistical significance.
RESULTS
Fifty patients were included in each group. Table 1 shows the patient characteristics and baseline values of the outcome variables. Table 2 shows a summary of the important intraoperative data. In both data sets (Tables 1 and 2) , there were no significant differences. Table 3 shows the hemodynamic data during surgery. Epidural anesthesia was not attempted in 2 patients in each group for a platelet count Ͻ80 ϫ 10 9 /L. No patient died in this study. Major complications included sepsis (2 patients in each group), bleeding (2 patients in each group), and biloma (1 patient in the sevoflurane group). The mean hospital stay was 2 days shorter in the propofol group (14 vs 16 days) but without statistical significance. The degree of ischemia and reperfusion injury of the liver was assessed by postoperative peak serum ALT and AST levels. Transaminase levels peaked between the first and the third postoperative day. The sevoflurane group had slightly lower peak ALT and AST levels than the propofol group, but these were not statistically different (P Ͼ 0.05) ( Table 4 ). Unadjusted and adjusted results in multivariable linear regression analyses (analysis of covariance) were almost identical. Unadjusted results are presented in Table 4 . Other liver function tests such as bilirubin and alkaline phosphatase, as well as peak white blood cell levels and creatinine, were not different between groups (P Ͼ 0.05). The results of subgroup analyses comparing cirrhotic and noncirrhotic patients are presented in Table 5 . Although the serum levels of ALT/AST were higher in cirrhotic patients than in noncirrhotic patients, there were no significant differences between these subgroups (P Ͼ 0.05). Figures 1 and 2 show ALT and AST levels over 6 postoperative days, respectively.
DISCUSSION
We compared the effect of volatile anesthetics with propofol anesthetics on liver function in patients undergoing liver resection with inflow occlusion. There were no significant differences in postoperative liver function as measured by serial transaminase levels, or in clinical outcomes in the 2 groups.
Numerous strategies have been designed to reduce ischemia/reperfusion injury after liver resection. Two protective strategies to prevent ischemic-reperfusion injury have been clinically accepted: ischemic preconditioning 4, 9 and intermittent clamping 11 of the portal triad. Both procedures require a surgical intervention and prolong the overall time of the surgical procedure. Hence, a pharmacological approach not requiring additional surgical procedures may be a more attractive alternative than the established surgical strategies. In this study, we wanted to address whether the anesthetic affects postoperative hepatic function in patients undergoing elective liver resection with inflow occlusion.
Many factors contribute to hepatic injury and outcomes after liver resection. Among these, patient characteristics such as the severity of liver disease and surgical complications are common contributors to poor postoperative outcome. In this study, the patient characteristics, baseline values of the outcome variables, and the data of surgeryrelated events showed that the 2 patient groups were truly equivalent ( Tables 1 and 2 ). In addition, surgery-related factors (Pringle time, size of excised liver, and blood loss) and baseline transaminases and bilirubin levels were considered in multivariable linear regression analyses.
The effect of sevoflurane on hepatic function has been examined in several studies. The study conducted by Ebert and Arain 12 suggested that sevoflurane, but not propofol, was associated with increased liver injury in patients undergoing hepatectomy without inflow occlusion, but the liver function tests in sevoflurane-exposed patients were in the upper limits of normal. The study by Beck-Schimmer et al., 13 however, suggested that sevoflurane preconditioning was protective against ischemia/reperfusion injury during liver resection. Sevoflurane preconditioning was shown to prevent hepatic injury, defined by transaminase levels, and improve clinical outcome. In the volatile preconditioning group, the expression of inducible nitric oxide synthase upon reperfusion significantly increased compared with the baseline value, which points to a possible protective role of nitric oxide in pharmacological preconditioning. In a rat hepatic ischemia/reperfusion injury model, clinically Data are mean (SD). ALT ϭ alanine aminotransferase; AST ϭ aspartate aminotransferase; ALP ϭ alkaline phosphatase; WBC ϭ white blood cell. relevant concentrations of sevoflurane given before, during, and after hepatic ischemia protected the liver against ischemia/reperfusion injury. Increased hepatic adenosine triphosphate and energy levels decreased hepatocyte injury, and the hepatic tissue blood flow almost completely recovered after ischemia/reperfusion in the sevoflurane group. 14 The study by Imai et al. 15 suggested that volatile anesthetics may protect the fasted liver from early, neutrophil-independent, ischemia/reperfusion injury by acting during the reperfusion phase. Sevoflurane reduced hepatic oxygen consumption and attenuated lactate dehydrogenase release during reperfusion. Sevoflurane preconditioning may provide a new and easily applicable therapeutic option to protect the liver in hepatectomy. Propofol is an IV sedative-hypnotic drug frequently used in anesthesia and intensive care that not only inhibits lipid peroxidation, but also enhances the cellular antioxidant defense system in several tissues including brain, liver, and heart. 16, 17 Propofol pretreatment attenuates ischemia/reperfusion-induced intestinal epithelial apoptosis, which might be attributable to its antioxidant property modulating the ceramide pathway. 18 Propofol improves survival of liver cells in rat hepatocyte suspensions exposed to oxidant injury by a free radical generator 2,2Ј-azobis (2-amidinopropane) dihydrochloride (AAPH). 19 Propofol protects hepatic L02 cells from hydrogen peroxide-induced apoptosis, partly through activating the MEK-ERK pathway and further suppressing Bad and Bax expression. 20 The study by Shimono et al., however, suggested that propofol did not have a protective effect against hypoxia/reoxygenation injury in rat liver slices. 21 The effects of pharmacological preconditioning with propofol in patients undergoing liver resection with inflow occlusion remain to be determined.
In our study, patients with biopsy-proven cirrhosis did not have worse postoperative liver dysfunction than those without cirrhosis, likely because the cirrhotic patients had mild disease, indicated by the Model for End-Stage Liver Disease score. In addition, the period of ischemia was short; longer ischemic stress may have unmasked a difference between cirrhotic and noncirrhotic patients. Previous studies suggest that patients with early-stage cirrhosis can tolerate as much as 60 to 75 minutes of inflow occlusion during hepatectomy without serious postoperative liver decompensation. [22] [23] [24] Our study had several limitations. It is not possible to determine from our results whether sevoflurane and propofol are protective in the setting of hepatic ischemia/reperfusion injury. Second, patients were not systematically assessed for hepatic fibrosis or steatosis, both risk factors for liver dysfunction after liver ischemia. In conclusion, our data suggest that sevoflurane or propofol can be used safely in patients undergoing hepatectomy with inflow occlusion, and that there is no advantage of one drug over the other.
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